Clinical efficacy of aripiprazole and cerebral circulatory system therapy in the treatment of schizophrenia
Objective:To explore the clinical efficacy of aripiprazole and cerebral circulatory system therapy in pa-tients with schizophrenia(SP).Methods:A total of 116 SP patients who were admitted in the Second People's Hospital of Zhumadian from January 2022 to June 2023 were selected,and randomly divided into the observation group(58 ca-ses,aripiprazole and cerebral circulatory system therapy)and the control group(58 cases,aripiprazole).The clinical ef-ficacy,memory function,cognitive function,neurokines,and adverse reactions in both groups were compared.Results:The total effective rate of the observation group was higher than that of the control group,with statistical significance(P＜0.05).After treatment,the scores of wechsler memory scale(WMS),montreal cognitive assessment scale(MoCA),brain-derived neurotrophic factor(BDNF),nerve growth factor(NGF),neurotrophin-3(NT-3)and glial-derived neurotrophic factor(GDNF)all increased in the two groups,and the difference was statistically significant(P＜0.05).There was no signifi-cant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion:The combination of aripiprazole and cerebral circulatory system therapy treatment for SP patients can improve clinical efficacy,improve memory and cognitive function,regulate nerve factor levels,and have high safety.
schizophreniaaripiprazolecerebral circulatory system therapyclinical effects
万方数据
维普
